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DOI 10.1016/j.ccr.2009.12.047SUMMARYOvarian cancer is a leading cause of death from gynecologic malignancies. Treatment for advanced-stage
disease remains limited and, to date, targeted therapies have been incompletely explored. By systematically
suppressing each human tyrosine kinase in ovarian cancer cell lines by RNAi, we found that an autocrine
signal-transducing loop involving NRG1 and activated ErbB3 operates in a subset of primary ovarian cancers
and ovarian cancer cell lines. Perturbation of this circuit with ErbB3-directed RNAi decreased cell growth
in three-dimensional culture and resulted in decreased disease progression and prolonged survival in a
xenograft mouse model of ovarian cancer. Furthermore, a monoclonal ErbB3-directed antibody (MM-121)
also significantly inhibited tumor growth in vivo. These findings identify ErbB3 as a potential therapeutic
target in ovarian cancer.INTRODUCTION
Some tumors are dependent upon the continuous activity of
a single oncogene for their proliferation and survival despite their
having accumulated other genetic and epigenetic changes
(Sharma and Settleman, 2007; Weinstein, 2002; Weinstein and
Joe, 2006, 2008). Although only a few such ‘‘addicting’’ onco-Significance
In this report is described a distinct role for an NRG1-driven/act
human ovarian cancer cells. In a murine xenograft model, tre
ErbB3-directed monoclonal antibody resulted in significantly
vated-ErbB3 phenotype is present in a significant fraction o
together, these results strongly suggest that ErbB3 and/or NR
in advanced-stage ovarian cancer.
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antagonize the functions of some of their products has signifi-
cantly changed the field of cancer treatment. Such ‘‘targeted’’
therapies offer potential advantages, including a reduction in
nonspecific drug-associated toxicity. Furthermore, the identifi-
cation of patient populations whose tumors are addicted to an
oncogene of interest has made possible the first steps towardivated-ErbB3 autocrine loop in promoting cell proliferation in
atment with either an inducible ErbB3-directed RNAi or an
decreased tumor growth. Moreover, the NRG1-driven/acti-
f primary advanced-stage human ovarian cancers. Taken
G1 have the potential to serve as rational treatment targets
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priate patients. Of particular interest in targeted cancer therapy
research are the tyrosine kinases. Some of these enzymes are
central regulators of cell signaling pathways that control a variety
of cellular homeostatic processes that, when corrupted, trigger
abnormal cell proliferation, disorderly differentiation, enhanced
survival and motility, and/or invasion by relevant tumor cells
(Hunter, 1998; Mustelin and Hunter, 2002). In some human
tumors, certain tyrosine kinases have become hyperactivated
through mutation, and their activation can lead to a state of
oncogene dependence (Blume-Jensen and Hunter, 2001;
Sharma and Settleman, 2007). Drugs that inhibit oncogenic tyro-
sine kinases, such as imatinib, erlotinib, and trastuzumab, have
become effective cancer therapies, further underlining the
importance of these enzymes as valuable drug targets (Mustelin
and Hunter, 2002).
Ovarian cancer is the leading cause of death from gynecologic
malignancy in the United States, with an estimated 21,550 cases
and 14,600 deaths occurring in 2009 (Jemal et al., 2009). Surgery
and platinum-based chemotherapy remain the standard of care
for initial treatment. Although initial response rates are high, the
disease recurs in a large majority of patients and becomes
increasingly platinum resistant (Modesitt and Jazaeri, 2007).
In a setting of platinum-resistant ovarian cancer, response rates
to subsequent chemotherapy are low, and death regularly
ensues. Thus, new therapeutic approaches are needed.
The identification of potential addicting oncogene targets
remains incompletely explored in ovarian cancer. Multiple
protein tyrosine kinases, including EGFR, Her-2, ErbB3, PDGFR,
and EphA2, have been found to be overexpressed in malignant
ovarian tumors by comparison with normal ovarian tissue
(Apte et al., 2004; Henriksen et al., 1993; Psyrri et al., 2005;
Seiden et al., 2007; Shepard et al., 1991; Tanner et al., 2006;
Thaker et al., 2004). However, it remains unclear what roles these
tyrosine kinases play in tumor development and survival. Indeed,
to date, no specific addicting target oncoprotein has been
identified and validated in ovarian cancer.
RNA interference (RNAi) represents a powerful tool that can
be used in a comprehensive manner to search for genes that,
when depleted, trigger cell death or proliferation arrest in tumor
cells. In this study, we searched for such genes in ovarian cancer
cell lines using a previously described, lentivirally delivered
short-hairpin RNA (shRNA) library targeting tyrosine kinases
(Moffat et al., 2006). In addition, we explored the mechanism
by which the product of the tyrosine kinase gene that emerged
as the leading validated hit in the screen supports ovarian
cancer cell survival or proliferation. We also investigated
whether the same gene product is active in primary ovarian
cancer cells.
RESULTS
ErbB3 Supports Ovarian Cancer Cell Proliferation
Members of a library consisting of 387 lentiviruses, each
harboring a unique shRNA targeting one of 80 human tyrosine
kinases, were introduced individually into SKOV3 ovarian cancer
cells (see Table S1 available online). shRNAs targeting 6 of the
80 kinases screened scored positively (Table S1, highlighted
rows; see Supplemental Experimental Procedures for criteriaof positive hits). Sixty-two shRNAs directed at these kinases as
well as at kinases that were hit only once in the SKOV3 screen
were selected for a secondary screen performed in OVCAR8
cells, another ovarian cancer cell line. In this screen, EphA4,
ErbB3, and KDR again scored positively, with ErbB3 scoring
as the strongest hit in both ovarian cancer cell lines (Figure 1A).
Validation studies were performed by transfecting OVCAR8 cells
with four nonoverlapping ErbB3-directed small interfering RNAs
(siRNAs), each of which also induced cell toxicity as measured
by an ATP-based CellTiter-Glo assay, consistent with the results
of the initial screens (Figure 1B). All of these siRNA sequences
efficiently reduced endogenous ErbB3 protein expression to
near-background levels (Figure 1B) and significantly decreased
surface ErbB3 levels as revealed by FACS analysis (data not
shown). No evidence of significant cell death was observed by
FACS analysis or Annexin-V staining following siErbB3 transduc-
tion, suggesting that the observed effects in OVCAR8 cells are
secondary to inhibition of cell proliferation (data not shown).
To further test whether the antiproliferative effect of ErbB3
RNAi on OVCAR8 cells was specific to ErbB3 loss, we created
an ErbB3 cDNA species that was resistant to the designated
siRNA through the introduction of ‘‘silent’’ base-pair mutations
at the siRNA recognition site. Introduction of this siRNA-immune
ErbB3 cDNA into OVCAR8 cells significantly increased the
ErbB3 protein level, and this high level persisted even in the pres-
ence of siErbB3 (Figure 1C). The total level of activated ErbB3,
however, was not elevated much above that detected in naive
OVCAR8, suggesting that activation of ErbB3 is tightly regulated.
siErbB3 did reduce T308 AKT phosphorylation in OVCAR8 cells
transduced with vector alone as compared with control siRNAs
(Figure 1C). In the absence of exogenously added NRG1, the
ectopically overexpressed ErbB3 failed to rescue the defect in
cell proliferation, despite a partial restoration of both Y1289
phosphorylation of ErbB3 and T308 phosphorylation of AKT
(Figures 1C and 1D). However, significant biochemical and bio-
logical reversal of the effect of the siRNA was achieved
when NRG1 was added to cells containing the ectopically
overexpressed, siRNA-immune version of ErbB3 (Figures 1C
and 1D). This requirement for coexpression of ligand to achieve
significant rescue may reflect an absolute need for ligand
and otherwise insufficient endogenous ligand production by
OVCAR8 cells in this experimental setting. Moreover, because
five nonoverlapping ErbB3 shRNAs and four ErbB3 siRNAs
demonstrated a similar growth inhibition phenotype (Figure S1),
and exogenously expressed siRNA-immune ErbB3 cDNA
restored cell growth in the presence of NRG1, we conclude
that selective loss of ErbB3 function can inhibit the proliferation
of certain cultured ovarian cancer cells.
Comparison of the Effects of ErbB3 Depletion
on Ovarian Cancer Cell Lines with Different
ErbB3 Activation Status
Given the observations with SKOV3 and OVCAR8 cells, a collec-
tion of ovarian cancer cell lines was surveyed for their ErbB3
status (Figure 2A; EGFR and Her-2 status were also surveyed;
see Figure S2). Of 16 cell lines examined, ErbB3 was expressed
and constitutively activated in 9 and present but not activated
in 6. One cell line (HeyA8) did not express ErbB3. Activation of
ErbB3 was indicated by phosphorylation of Y1289 (Kim et al.,Cancer Cell 17, 298–310, March 16, 2010 ª2010 Elsevier Inc. 299
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Figure 1. Depletion of ErbB3 Inhibits OVCAR8 Proliferation
(A) Secondary shRNA kinase screen in which 15 hairpin sets, each of which scored at least one hit in the primary screen, were retested. Each bar represents the
effect of one hairpin; shRNAs directed against the same kinase are grouped together. Hairpin sets containingR2 hits in the secondary screen were considered
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Activated ErbB3/NRG1 and Ovarian Cancer1994; Soltoff et al., 1994). To determine whether cell proliferation
was perturbed when activated ErbB3 was depleted, we first
compared the response to forced ErbB3 depletion of two ovarian
cancer cell lines, OVCAR8 (which expresses and activates
ErbB3) and OVCAR5 (which expresses ErbB3 protein but does
not activate it). Three separate OVCAR5 and OVCAR8 sublines,
each carrying a different nonoverlapping tet-inducible shErbB3,
and a fourth subline carrying a tet-inducible ‘‘scrambled’’ shRNA
were established. In the absence of doxycycline, the proliferation
rate of all shRNA-carrying lines was comparable to that of control
cell lines. However, upon doxycycline induction of shErbB3
expression, proliferation of all of the shErbB3 OVCAR8 sublines
was substantially reduced (Figure 2B). In contrast, despite effi-
cient reduction of ErbB3 protein levels in OVCAR5 cells, the
same shErbB3 hairpins had only minimal or no effect on cell
proliferation (Figure 2C). The difference in response between
OVCAR8 and OVCAR5 cells to loss of ErbB3 suggests that cells
which constitutively activate ErbB3 are also dependent upon the
protein for cell proliferation, whereas those that produce but fail
to activate it are not. In keeping with this notion, SKOV3, another
ovarian cancer cell line that, like OVCAR8, expresses a high level
of activated ErbB3, was sensitive to doxycycline-induced
shErbB3 synthesis. In contrast, IGROV-1, an ovarian cancer
cell line that resembles OVCAR5 with respect to ErbB3 expres-
sion and activation, was not (Figure 2D). The NRG1, ErbB3,
and activated ErbB3 status, as well as the sensitivity to ErbB3
RNAi for a panel of ovarian cancer cell lines, is shown in Table
S2. In five of the lines tested for shErbB3 sensitivity, the NRG1
and phospho-ErbB3 phenotypes predicted the outcome of
depleting ErbB3, whereas in four cell lines with an NRG1/acti-
vated-ErbB3 phenotype, ErbB3 depletion did not result in cell
toxicity, suggesting that additional signal transduction events
may compromise a straightforward dependence upon ErbB3
or NRG1.
Existence of an NRG1/ ErbB3 Autocrine Loop
in Ovarian Cancer Cells
Certain mechanisms that could, in principle, lead to sustained
ErbB3 activation in OVCAR8 cells were evaluated. The entire
coding sequence of ERBB3 in 145 primary ovarian carcinoma
DNA samples was sequenced, and no somatic ERBB3 muta-
tions were detected (data not shown). A missense mutation
was identified in the ERBB2 open reading frame (G776V) in
OVCAR8 cells. However, shRNA-mediated depletion of neither
EGFR nor Her-2 in OVCAR8 led to ErbB3 deactivation (data
not shown). These cells do not synthesize detectable amounts
of ErbB4 (data not shown). Because it had been reported previ-positives in that screen and marked in red. The blue line denotes the point repre
obtained in this assay. See Table S1 for complete results of the screen.
(B) siRNA species directed against ErbB3 inhibited OVCAR8 proliferation. Left: Er
siErbB3 species. Right: proliferation of OVCAR8 cells treated with either control siR
(p < 0.05, Student’s t test). See also Figure S1 for effects of shErbB3.
(C) Biochemical effects of overexpressing an ErbB3 cDNA immune to ErbB3 siR
Experimental Procedures).
(D) Effect on OVCAR8 proliferation of overexpressing an ErbB3 cDNA immune to E
cells, growth of ErbB3 siRNA cells was significantly different from siGL2- and siG
siRNA-resistant ErbB3 cDNA in the presence of exogenous NRG-1b, growth of c
cells (Dp < 0.05, Student’s t test).
Error bars represent ± SD.ously that some ovarian cancer cells secrete the ErbB3 ligand
NRG1 (Gilmour et al., 2002), we tested for the presence of an
NRG1/ErbB3 autocrine loop in OVCAR8 and other lines that
produce and activate ErbB3.
RT-PCR revealed the presence of NRG1 mRNA in OVCAR8
and SKOV3 cells, both of which contain activated ErbB3, but
not in OVCAR5 or IGROV-1 cells, which express ErbB3 but do
not constitutively activate it (Figure 3A, left). Immunoblotting of
conditioned medium (CM) derived from OVCAR8 cultures using
an antibody directed against NRG1 revealed an 50 kD band
(Figure 3A, middle). This band was absent from OVCAR5 CM
(not shown). Transfer of CM from either OVCAR8 or SKOV3 to
OVCAR5 induced activation of ErbB3 and AKT in the latter
(Figure 3B). Moreover, two NRG1-directed siRNAs each resulted
in a significant reduction in the abundance of the 50 kD band in
OVCAR8 CM (Figure 3A, middle). Similarly, CM obtained from
NRG1 siRNA-treated OVCAR8 cells was less effective in acti-
vating ErbB3 and AKT in OVCAR5 cells than CM from control
siRNA-treated cells (Figure 3A, right). In addition, OVCAR8 cells
treated with NRG1 siRNAs (1.4 and 1.9) revealed less ErbB3
activation than the control (Figure 3C, left), further supporting
the hypothesis that NRG1 is an autocrine stimulator of ErbB3
activation in OVCAR8.
To investigate the role of NRG1 in cells bearing a putative
NRG1/activated-ErbB3 autocrine phenotype, the effect of
NRG1-directed RNAi on cell proliferation was tested. Multiple
siRNAs directed against NRG1 resulted in OVCAR8 proliferation
inhibition (Figure S3A). This effect was reversed by expression
of an NRG1 cDNA that was immune to one of the two siRNAs
depicted in Figure 3C (i.e., siNRG1.4). In contrast, no reversal
was observed when cells expressing the siNRG1.4-immune
NRG1 cDNA were transfected with a different NRG1-directed
siRNA (siNRG1.9) to which the cDNA was not immune. As with
tet-inducible shRNAs directed at ErbB3, doxycycline-mediated
synthesis of two shRNAs directed at NRG1 resulted in significant
toxicity in OVCAR8 and SKOV3 cells but only minimal toxicity in
OVCAR5 and IGROV-1 cells, neither of which produce NRG1
mRNA (Figures S3B–S3D).
We also searched for evidence of an NRG1/ErbB3 autocrine
loop in fresh primary tumor cells derived from malignant ascites
fluid obtained from patients with advanced ovarian cancer. Of
tumor cells derived from the 20 samples that were analyzed, 6
expressed comparatively high levels of NRG1 mRNA (Figure 4A).
Three of these NRG1-expressing samples were subsequently
tested further (DF14, DF25, DF26). Each contained activated
ErbB3 that could be coimmunoprecipitated with the p85 subunit
of PI3 kinase (Figure 4B), consistent with the hypothesis that,senting one standard deviation below the mean value of all CellTiter-Glo data
bB3 protein level in OVCAR8 cells treated with either control siRNA or different
NA or siErbB3. *significantly different from siGL2- or siGAPDH-treated sample
NA in the absence and presence of recombinant NRG1b (see Supplemental
rbB3 siRNA in the absence and presence of NRG1b. In the vector-only control
APDH-treated samples (*p < 0.05, Student’s t test). In cells stably expressing
ells treated with ErbB3 siRNA was significantly greater than in the vector-only
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Figure 2. ErbB3 Is Activated in Multiple Ovarian Cancer Cell Lines
(A) Study of ErbB3 expression and activation in various ovarian cancer cell lines. Left: lysates were immunoprecipitated with anti-ErbB3 antibody and then blotted
with anti-phospho-ErbB3 (Y1289) and anti-PI3K p85 antibody. The Y1289 blot was then stripped and reprobed with anti-ErbB3 antibody. *5 mg of lysate was
applied for TOV21G and SKOV3 cells due to the relatively low abundance of ErbB3 in these cell lines. For all other cell lines, 1 mg of lysate was used.4, a back-
ground band;/, p85. Right: ErbB3 expression was not detected in normal ovarian surface epithelial cells. See also Figure S2 for EGFR and Her-2 status.
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Figure 3. OVCAR8 ErbB3 Phosphorylation Is Mediated by NRG1 which, when Depleted, Results in Proliferation Inhibition
(A) Left: NRG1 mRNA is present in OVCAR8 and SKOV3 cells but not in OVCAR5 or IGROV-1 cells. Middle: NRG1-directed RNAi depleted the CM of OVCAR8 of
the 50 kD anti-NRG1 reactive band as compared to mock or siGL2. Right: it also reduced the ability of OVCAR8 CM to mediate phosphorylation of ErbB3 in
OVCAR5 cells.
(B) Transfer of CM from OVCAR8 or SKOV3 or recombinant NRG1 polypeptide mediated the phosphorylation of ErbB3 in OVCAR5.
(C) Expression of an NRG1 cDNA resistant to the NRG1-directed siRNA siNRG1.4 led to restoration of intrinsic ErbB3 phosphorylation in OVCAR8 and prevention
of toxicity when the cells were treated with siNRG1.4; this did not occur in cells exposed to siNRG1.9, to which the cDNA is not immune. *significantly different
from mock and siGAPDH samples (p < 0.05, Student’s t test). Error bars represent ± SD. See Figure S3 for effect of NRG1 depletion on ovarian cancer cell lines.
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Activated ErbB3/NRG1 and Ovarian Cancerin vivo, the PI3 kinase pathway had been engaged through
NRG1-driven activation of ErbB3. In one of these primary cell
preparations (DF14), ErbB3 coimmunoprecipitated with both(B) Doxycycline-induced shErbB3 inhibits OVCAR8 cell proliferation. Top: ErbB
shErbB3 species or a doxycycline-inducible control shRNA in the presence or abs
doxycycline-inducible shRNAs in the presence or absence of doxycycline.
(C) Top: OVCAR5 cell expression of ErbB3 before and after doxycycline-induced
limited effects on OVCAR5 proliferation.
(D) Effect of inducible shErbB3 on IGROV-1 (left) and SKOV3 (right) cells. *signifi
represent ± SD. See Table S2 for a summary of additional ovarian cancer cell linHer-2 and ErbB4 (Figure 4C). In addition, CM from some of the
primary tumor cell samples that express NRG1 mRNA (DF05,
DF14) activated ErbB3 in OVCAR5 cells (which express but do3 protein level in OVCAR8 cells carrying three different doxycycline-inducible
ence of doxycycline. Bottom: OVCAR8 proliferation in cells expressing different
ErbB3 hairpin expression. Bottom: doxycycline-induced shErbB3 elicited only
cantly different from shControl sample (p < 0.05, Student’s t test). Error bars
es.
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Figure 4. ErbB3 Is Expressed and Phosphorylated and NRG1 Is Expressed in a Subset of Primary Human Ovarian Cancers
(A) A subset of primary human ovarian cancer cells was analyzed for NRG1 mRNA, as detected by quantitative RT-PCR.
(B) ErbB3 is expressed and activated in a subset of primary human ovarian cancer cells. The p85 subunit of PI3K was coimmunoprecipitated in cells that phos-
phorylate ErbB3 on Y1289, consistent with active signaling through the PI3 kinase pathway.
(C) ErbB3 interacts with ErbB4 and Her-2 in primary DF14 ovarian cancer cells. DF14 lysates were immunoprecipitated with either control IgG or antibodies
directed at either ErbB4, Her-2, or ErbB3, followed by immunoblotting with either anti-ErbB3 or anti-ErbB4.
(D) Conditioned medium from primary human ovarian cancer cells that intrinsically phosphorylate ErbB3 elicited ErbB3 phosphorylation and PI3K/AKT pathway
activation following transfer to OVCAR5 cells.
(E) Top: ErbB3-directed shRNA effectively reduced ErbB3 protein expression levels in DF14 cells. Bottom: three different shErbB3s resulted in growth inhibition in
DF14 cells. *significantly different from shControl (p < 0.05, Student’s t test). Error bars represent ± SD.
(F) A monoclonal antibody directed against the ErbB3 ectodomain (MM-121) abolished endogenous DF14 ErbB3 phosphorylation.
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Activated ErbB3/NRG1 and Ovarian Cancernot activate ErbB3) (Figure 4D). Depletion of ErbB3 by shRNA in
a culture of one of the primary ovarian cancer cell strains that
demonstrates this NRG1/activated-ErbB3 phenotype (DF14)304 Cancer Cell 17, 298–310, March 16, 2010 ª2010 Elsevier Inc.resulted in decreased cell proliferation (Figure 4E), supporting
the notion that ErbB3 can play an important role in supporting
cell growth in primary ovarian cancers. Furthermore, incubation
Cancer Cell
Activated ErbB3/NRG1 and Ovarian Cancerof the same cells, namely DF14, with a monoclonal antibody
directed at the ErbB3 ectodomain (MM-121) abrogated phos-
phorylation of ErbB3 in these cells (Figure 4F). Taken together,
the above-noted data strongly suggest that ErbB3 is activated
by an NRG1-driven autocrine circuit in certain ovarian cancer
cell lines and in a significant fraction of primary advanced-stage
ovarian cancers. As seen in Figure 4C, this activation may involve
ErbB3 heterodimerization with a suitable kinase-competent
ErbB family member (e.g., Her-2 or ErbB4).
Loss of ErbB3 Inhibits Growth in Three-Dimensional
Culture and Decreases Tumor Progression
in Mouse Xenograft Models
We also asked whether loss of ErbB3 inhibits growth of OVCAR8
cells in 3D culture, as represented in a spheroid formation assay.
Using a hanging-droplet method, spheroids were created from
OVCAR8 cells transduced with inducible ErbB3-directed or
control shRNAs. Induction of the shErbB3s with doxycycline
inhibited spheroid formation as compared with a scrambled
shRNA derivative. This effect was particularly pronounced in
the cell population that synthesized the 3293 shRNA (Figure 5A).
Given the cell-culture data suggesting that ErbB3 is indispens-
able for proliferation of human ovarian cancer cell lines that
display evidence of an autocrine NRG1/activated-ErbB3 circuit,
we also asked whether perturbation of this pathway affects
tumor progression in an intraperitoneal OVCAR8 xenograft
mouse model. Preinjection shRNA-mediated depletion of
ErbB3 followed by continuous doxycycline treatment of mice
that had been injected intraperitoneally with the pretreated cells
significantly decreased tumor progression compared with
controls, as measured by an increase in whole-animal luciferase
activity detected by in vivo bioluminescent imaging (Figure 5B).
Induction of two different ErbB3 hairpins by initiation of doxycy-
cline treatment after tumor establishment (reflected by an
increase in luciferase activity after intraperitoneal tumor cell
injection) reduced tumor progression and significantly improved
overall survival in both cases (Figures 5C and 5D). No suppres-
sion of tumor progression was detected following the induction
of a scrambled shRNA (Figure S4A). Of note, these in vivo effects
correlated with the results of the 3D culture seen in Figure 5A,
with induction of 3293 shRNA resulting in more significant
defects in spheroid formation and tumor regression in the mice
xenografts than 3982 shRNA. The difference in effect between
these two shRNA species may be explained by their differing
potencies in inducing rapid ErbB3 depletion in vivo and in
suspension culture (Figure S4B).
We also assessed the effects of an anti-ErbB3 ectodomain-
directed monoclonal antibody, MM-121 (Merrimack Pharma-
ceuticals; previously described in Schoeberl et al., 2009), which,
in biochemical assays, blocked both constitutive and NRG1-
stimulated ErbB3 phosphorylation in OVCAR8 cells and elicited
a small decrease in the OVCAR8 ErbB3 protein level (Figure S4C).
In the ex vivo spheroid assay, MM-121 resulted in a small but
consistent decrease in OVCAR8 spheroid growth (Figure 5E).
In a subcutaneous xenograft model of OVCAR8 cells, significant
inhibition of tumor growth was observed with MM-121 treatment
compared with control-treated mice (Figure 5F). These observed
antibody effects further underscore the importance of ErbB3
function for the maintenance of in vivo cell growth and suggestthat the NRG1/ErbB3 circuit may be a viable therapeutic target
in vivo.
DISCUSSION
A fraction of both established ovarian cancer cell lines and
primary ovarian cancer-derived cell collections display a pheno-
type in which ErbB3, a member of the ErbB family of cell-surface
receptor proteins, is activated. Activation of ErbB3 in a number
of these ovarian cancer cells appears to be mediated by
autocrine secretion of a known ErbB3 ligand, NRG1. In others,
however, this activation may be NRG1 independent. The auto-
crine NRG1/ErbB3-activation effects contribute to a major
biological outcome. When deprived of ErbB3 by RNAi, tumor
cell lines that feature an active NRG1/ErbB3 circuit experienced
a proliferation defect when grown on plastic surfaces, an effect
that was overridden when the same cells were forced to overex-
press a cognate RNAi-resistant ErbB3 cDNA in the presence of
exogenous NRG1 ligand. These same tumor cell lines also
demonstrated proliferation defects in the presence of NRG1
siRNA, and this effect could be overridden with the expression
of an RNAi-resistant NRG1 cDNA. The proliferation defects
observed with ErbB3 or NRG1 RNAi, thus, appear to be the
product of on-target effects of the relevant RNAi reagents. In
turn, these results indicate that this autocrine ErbB3-activating
circuit supports one or more key steps in the mechanism under-
lying the ex vivo proliferation of the cell lines of interest.
Furthermore, when OVCAR8, which is tumorigenic after intro-
duction into the peritoneal cavity of nude mice, was deprived of
ErbB3 in culture through induced synthesis of a specific hairpin,
de novo tumorigenesis was severely compromised. If the tumor
cells were grown in doxycycline-free media and then exposed to
the drug after the development of limited tumor growth in vivo,
subsequent tumor growth was also blocked. Prolongation of
the survival of the treated mice accompanied tumor growth
blockade. Because exposure of these cells to a scrambled
version of the ErbB3 hairpin led to no effect on tumor growth,
an on-target effect of the relevant ErbB3 hairpins appears to
be the basis for the in vivo tumor growth inhibition that was
observed. The relevance of ErbB3 as a potential therapeutic
target in ovarian cancer was supported by the ability of a system-
ically delivered, monoclonal anti-ErbB3 antibody to inhibit tumor
growth in vivo in a xenograft model of OVCAR8 cells.
A role for activated ErbB3 in ovarian cancer proliferation was
also suggested by analyses of primary ovarian cancer cells. A
significant portion (4 of 7) of a collection of primary ovarian
cancer cells freshly obtained from patients with advanced-stage
disease revealed the presence of activated ErbB3 that coimmu-
noprecipitated with the p85 subunit of PI3 kinase (PI3K), some-
times together with expression of NRG1 mRNA. Given this
evidence suggesting the presence of an NRG1/ErbB3 autocrine
phenotype with associated biochemical engagement of the PI3K
pathway in a subset of advanced-stage, primary, uncultured
ovarian cancers, one suspects that this pathway could serve
as a potential target in certain late-stage human ovarian cancers.
This notion is supported by the evidence that ErbB3-directed
RNAi inhibited cell growth of primary ovarian cancer cells that
demonstrated evidence of an NRG1-producing/activated-
ErbB3 phenotype (DF14) and that incubation of DF14 cells withCancer Cell 17, 298–310, March 16, 2010 ª2010 Elsevier Inc. 305
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Activated ErbB3/NRG1 and Ovarian Cancera monoclonal ErbB3 antibody, MM-121, abolished endogenous
Y1289 phosphorylation of ErbB3 in these cells. Thus, the
phenomena described here are applicable to primary ovarian
cancer cells in addition to established cell lines.
Of note, the effects of ErbB3 depletion were different when the
same target cell line was grown on a plastic surface and when it
was seeded as a peritoneal xenograft. In one case, ErbB3 deple-
tion triggered proliferation arrest without clear signs of cell death.
In contrast, in peritoneal xenografts, induction of the most potent
ErbB3 shRNA resulted in tumor regression, suggesting that cell
death had occurred. Whether this means that there is a depen-
dency for viability on the NRG1/ErbB3 pathway when OVCAR8
tumor cells are cultivated as a three-dimensional tumor mass
in vivo and a dependency for proliferation as opposed to viability
when cultivated on a plastic surface is unclear.
Circumstantial evidence consistent with a role for ErbB3 in
ovarian cancer is emerging (for reviews, see Lafky et al., 2008;
Sithanandam and Anderson, 2008). ErbB3 and NRG1 expres-
sion have been observed in ovarian tumors, with a higher
frequency in late-stage disease (Leng et al., 1997; Simpson
et al., 1995a, 1995b), but the association of NRG1 expression
and an activated ErbB3 circuit has not been previously
observed. ERBB3 gene amplification has been detected in
some ovarian papillary-serous adenocarcinomas (Tsuda et al.,
2004), and one study suggested that high ErbB3 expression is
associated with reduced clinical survival (Tanner et al., 2006).
Parenthetically, in neither OVCAR8 nor OVCAR5 is there
evidence for ERBB3 gene amplification, eliminating that
phenomenon as the source of robust protein expression in these
cells. Similarly, in neither OVCAR8 nor in the primary cell strain,
DF14, both of which express NRG1, did we detect any evidence
in single-nucleotide polymorphism array analyses for NRG1
gene amplification, ruling out that possibility as the source of
NRG1 expression in these lines (data not shown).
The therapeutic value of attacking ErbB3 in ovarian cancer
patients remains unclear, and clinical trials with antibodies and
small-molecule inhibitors directed at EGFR/Her-2, either of
which can serve as an ErbB3 heterodimeric partner, have not
demonstrated a significant benefit in ovarian cancer to date. In
a phase II study, trastuzumab failed to demonstrate significant
activity in ovarian cancers overexpressing Her-2, as assessed
by immunohistochemistry (Bookman et al., 2003). Similarly,
a phase II clinical trial with CI-1033, a pan-ErbB family inhibitor,
demonstrated minimal activity in platinum-refractory patients
(Campos et al., 2005). Moreover, pertuzumab, which inhibits
Her-2 dimerization, particularly with ErbB3, failed to demon-
strate significant benefit as a single agent in unscreened patients
(Gordon et al., 2006). Notably, in a recent analysis of a random-Figure 5. Effect of ErbB3 Depletion on OVCAR8 Spheroid Formation a
(A) Induction of shErbB3 inhibited OVCAR8 spheroid formation.
(B) Effect on tumor progression of inducing shErbB3 synthesis before inoculation
injection. Error bars represent ± SEM. See Figure S4A for effect of shControl.
(C) Effect on tumor progression of inducing shErbB3 synthesis in OVCAR8 cells
(D) Kaplan-Meier survival plots of mice carrying two different tet-inducible s
See Figure S4B for an analysis of the relative potencies of sh3293 and sh3982.
(E) Monoclonal anti-ErbB3 antibody (MM-121) inhibited OVCAR8 spheroid gro
Error bars represent ± SD.
(F) Monoclonal anti-ErbB3 antibody (MM-121) significantly inhibited OVCAR8
See Figure S4C for biochemical effect of MM-121 in OVCAR8 cells.ized double-blind phase II trial comparing gemcitabine
combined with placebo against gemcitabine combined with
pertuzumab, patients with ErbB3 mRNA levels below the median
observed in the study experienced significantly longer progres-
sion-free survival when treated with gemcitabine/pertuzumab
compared with gemcitabine/placebo (Makhija et al., 2010). The
mechanistic explanation for this remains unknown, and ErbB3
protein level and activation status were not examined in this
study.
Despite the above-noted findings, the observation reported
here of a functional NRG1/ErbB3 autocrine loop in a subset of
ovarian cancer cells and cell lines and the potential importance
of this pathway in maintaining ovarian cancer tumor growth
suggests that this may be a population in which ErbB3-directed
therapies should be considered. Given the observed interaction
of ErbB3 with at least two ErbB family members, both of which
are known to be enzymatically active, in both primary tumor cells
(Figure 4C) and established cell lines (data not shown), combina-
tion treatment with agents that target ErbB3 and the relevant
ErbB family members is also worth exploration.
ErbB3 can contribute to the function of Her-2 in sustaining
cell transformation and tumor development (Holbro et al.,
2003; Lee-Hoeflich et al., 2008). In breast cancer cells, resis-
tance to toxicity from EGFR- or Her-2-directed small-molecule
inhibitors could be mediated by restoration of ErbB3 phosphor-
ylation, the mechanism of which may be due to increased ErbB3
localization to the cell surface (Sergina et al., 2007). Upon ErbB3
depletion, these cells again became sensitive to the effects
of gefitinib (Sergina et al., 2007). Similarly, in an EGFR mutant-
containing cell line that was initially sensitive to gefitinib,
development of gefitinib resistance could be attributed to ampli-
fication of MET, which resulted in activation of ErbB3 through
selective tyrosine phosphorylation. This, in turn, triggered unreg-
ulated AKT signaling (Engelman et al., 2007). These studies
suggest that, in certain strains ofHER-2-amplified breast cancer
and mutant EGFR-producing lung cancer cells, activated ErbB3
plays a role in the development of resistance to inhibitors of
Her-2 and EGFR kinase function. However, in principle, it might
not be the primary driver of cancer cell proliferation and/or
survival in these settings. In contrast, the data described here
suggest that, in some ovarian cancer cells, ErbB3 is a primary
stimulus to sustained cancer cell proliferation both in vitro and
in vivo.
ErbB3, although a key member of the pathway(s) that triggers
cultured cell proliferation and subsequent tumor development, is
not sufficient to mediate these processes in isolation. The
protein, even when overexpressed, must be activated to trans-
duce relevant neoplastic growth signals. Two lines of evidencend Tumor Progression
of OVCAR8 cells into nude mice, with continued doxycycline treatment after
after tumor establishment. Error bars represent ±SEM.
hErbB3s. Mice were either treated with doxycycline or not, as indicated.
wth. *significantly different from control sample (p < 0.05, Student’s t test).
tumor growth in vivo in a xenograft model. Error bars represent ± SEM.
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Activated ErbB3/NRG1 and Ovarian Cancersupport this claim. First, NRG1 depletion elicited proliferation
arrest of OVCAR8 and SKOV3 cells, both NRG1-producing/
activated-ErbB3-containing lines. Second, OVCAR5 cells, a line
of ovarian cancer cells characterized by relatively high levels of
ErbB3 but no NRG1 expression, do not demonstrate ErbB3 acti-
vation; these cells, in turn, are not sensitive to either ErbB3 or
NRG1 depletion. In addition, NRG1 exposure triggered a marked
increase in AKT phosphorylation/activation, presumably through
a PI3K activation step. Thus, it seems reasonable to hypothesize
that NRG1 synthesis and its binding to the ErbB3 ligand-binding
domain or the existence of some other source of ErbB3 activa-
tion is required to elicit neoplastic effects in some ErbB3-
producing ovarian cancer cells. In keeping with this hypothesis,
others have failed to detect ERBB3 mutations in 96 primary
human ovarian cancers, suggesting that somatic ERBB3 muta-
tion is not a prominent pathway leading to its ovarian cancer-
associated activation (R.K.T. and M.M., unpublished data).
Other tyrosine kinases can activate ErbB3. In mammary cancer
cells, c-Src was shown to bind to ErbB3, and a c-Src family kinase
inhibitor reduced ErbB3 phosphorylation (Contessa et al., 2006;
Ishizawar et al., 2007; Zhang et al., 2007). More recently, as
mentioned above, Engelman et al. reported that MET amplifica-
tion leads to ErbB3 activation in the presence of an EGFR inhibitor
(Engelman et al., 2007) and further demonstrated the presence of
a MET/ErbB3/PI3K complex in these cells. Of note, we sought
and failed to detect either MET activation or dependence on
MET for the viability or proliferation of the ovarian cancer cells
we tested. Conceivably, these are present in other primary
ovarian cancer cell collections. Furthermore, in their paper, Ser-
gina et al. demonstrated that AKT elicits a negative regulatory
effect on ErbB3 phosphorylation, because PI3K inhibitors upre-
gulated ErbB3 phosphorylation in mammary cancer cells that
had been chronically exposed to an EGFR inhibitor(s) (Sergina
et al., 2007). These data suggest the existence of a complex
picture of the roles of certain ErbB family members, and of
ErbB3 in particular, in cancer development and maintenance.
Finally, it is currently unclear when in the development of
ovarian cancer ErbB3 activation takes place and whether,
when such cells are first detected during tumor development,
they represent all or only a fraction of available tumor cells.
This notwithstanding, the findings cited here imply that the
NRG1/ErbB3 circuit is active in primary ovarian cancer cells
freshly obtained from certain advanced-stage patients. They
also suggest that ErbB3- and/or NRG1-directed therapy is worth
further experimental evaluation as potential treatment in the
subset of human ovarian cancers in which there is an NRG1/
ErbB3 autocrine growth-promoting phenotype. Phase I clinical
trials are currently ongoing with ErbB3-directed monoclonal
antibodies, and further exploration of the clinical efficacy of
these or any other anti-ErbB3 agents currently in development
in ErbB3-activated ovarian cancer is of interest.
EXPERIMENTAL PROCEDURES
Tyrosine Kinase shRNA Screen and Validation
See Supplemental Experimental Procedures for details.
Reagents and Antibodies
Antibodies directed at pErbB3 (Y1289), pAKT (T308), pAKT (S473), pMAPK
(T202/T204), total MAPK, and total AKT were obtained from Cell Signaling308 Cancer Cell 17, 298–310, March 16, 2010 ª2010 Elsevier Inc.Technology. Anti-ErbB3 C-terminal region Ab (clone 2F12) was from Lab
Vision. Mouse monoclonal anti-PI3K p85 was from Upstate Biotechnology.
Anti-NRG1-b-1 ECD monoclonal antibody (clone 147705) and recombinant
human NRG1-b-1 ECD were from R&D Systems.
Plasmids and Cell Lines
Human ErbB3 cDNA (a gift from Dr. Lewis Cantley) was subcloned in the XhoI
and NotI sites of pOZ-FH-C (Nakatani and Ogryzko, 2003). The primer
sequences for subcloning ErbB3 cDNA were: 50-gttaacgtcgacatggatagggc
gaacgacgctctg-30 and 50-gttaacagcggccgcttacgttctctgggcattagcc-30. An
ErbB3 siRNA-resistant ErbB3 cDNA clone was generated with a QuikChange
XL Site-Directed Mutagenesis Kit (Stratagene) using the primers 50-cccgggtta
gaggaggaagacgtaaatggctatgtcatgccagatac-30 and 50-gtatctggcatgacatagcc
atttacgtcttcctcctctaacccggg-30. Endogenous human NRG1 cDNA was cloned
from OVCAR8 cells using the primer sequences 50-tggaggcggccgcttatacagca
atagggtcttgg-30 and 50-gttaacgcggccgctgaaccatggccgagcgcaaagaaggcag-30
and subcloned into pBabe-hygro (Morgenstern and Land, 1990). NRG1
siRNA-resistant NRG1 cDNA clones were generated with a QuikChange XL
Site-Directed Mutagenesis Kit using the primers 50-gaatactcctctctcaggttt
aaatggtttaaaaatgggaatgaattg-30 and 50-caattcattcccatttttaaaccatttaaacctgag
agaggagtattc-30.
To generate OVCAR8 cells carrying an siRNA-resistant ErbB3 mutant allele,
293FT cells were transfected with 1 mg of pOZ-FH-C carrying an siRNA-resis-
tant ErbB3 cDNA and an IL-2 cDNA together with packaging plasmids, in the
presence of Lipofectamine2000 (Invitrogen). Culture supernatants containing
this siRNA-resistant ErbB3 and IL-2-encoding retrovirus were harvested
48 hr after transfection. Polybrene (4 mg/ml) was added to all viral superna-
tants prior to infection of OVCAR8 cells. Forty-eight hours after infection,
infected cells were purified on anti-IL2-receptor antibody (Upstate Biotech-
nology) -coated Dynabeads (Invitrogen), as previously described (Nakatani
and Ogryzko, 2003). OVCAR8 cells expressing NRG1 cDNAs for experiments
involving cognate NRG1 siRNAs were generated by transfection of 293FT cells
with 1 mg of suitable pBabe-hygro-NRG1 DNA together with packaging
plasmids in the presence of Lipofectamine2000. Culture supernatants con-
taining the desired NRG1 cDNA retrovirus were used to infect OVCAR8
cells. Forty-eight hours after infection, cells were selected for hygromycin
resistance.
OVCAR8 cells carrying doxycycline-inducible shErbB3 or control shRNA
were generated as follows. Sense and antisense oligonucleotides for shErbB3,
namely shErbB3-3982, shErbB3-3293, shErbB3-4160, shErbB3-475, and
shControl (for oligo sequences, see below) were annealed, phosphorylated
with T4 kinase, and inserted into the AgeI and EcoRI sites of a ‘‘tet-on’’
PLKO vector (described in Wee et al., 2008). The resulting plasmids were
then packaged and used to infect OVCAR8 cells. Infected OVCAR8 cells
were selected for puromycin resistance and then pooled for subsequent use.
SKOV3, OVCAR8, and OVCAR5 were purchased from the American Type
Culture Collection. Human ovarian surface epithelial cells were provided
courtesy of Dr. Sam Mok. The other lines reported here were available in
our laboratories. All cell lines were cultured in RPMI 1640 (Invitrogen)
supplemented with 10% fetal bovine serum, 13 Pen/Strep (Invitrogen),
and 13 glutamine (Invitrogen). Primary cell strains were cultured in RPMI
1640 supplemented with 10% fetal bovine serum and 13 antibiotic-
antimycotic (Invitrogen). Cells were incubated at 37C in a 5% CO2-containing
atmosphere.
Primary Cells
Primary cells were obtained from patients with advanced ovarian cancer
at Dana-Farber Cancer Institute (DFCI) who underwent paracentesis for
malignant ascites or debulking surgery under protocols approved by the
Dana-Farber/Harvard Cancer Center Institutional Review Board (DFHCC
IRB) and the Partners Human Research Committee. Consent from patients
was obtained as per IRB guidelines. Ascites fluid was processed and tumor
cells were purified according to a previously described protocol (Clauss
et al., 2010). The epithelial nature of the cells for the cell packs was confirmed
by EpCAM and HE4 antibody immunostaining. Only primary lines that were
greater than 80% epithelial tumor cells after enrichment were selected for
analysis. RNA was extracted using TRIzol. RNA- and protein-containing
lysates were prepared from samples of fresh cells.
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Activated ErbB3/NRG1 and Ovarian CancerCell Extracts, Western Blotting, and Immunoprecipitation
Modified SDS-free RIPA buffer (0.25% Na deoxycholate, 50 mM Tris-HCl
[pH 7.4], 1% NP40, 150 mM NaCl, 1 mM EDTA) containing freshly added
50 mM NaF, 0.4 mM sodium orthovanadate, and complete protease inhibitor
cocktail tablets (Roche) was used for extract preparation. For immunoprecip-
itation with mouse monoclonal Abs, lysates were incubated overnight with
antibodies, anti-mouse immunoglobulin, and protein A beads at 4C. Immuno-
precipitates were washed three times with lysis buffer and resolved by SDS gel
electrophoresis, and the separated proteins were blotted onto nitrocellulose
membranes that were developed with appropriate antibodies.
RT-PCR
mRNA from cell lines was extracted with RNeasy Mini Kits (QIAGEN). Reverse
transcription was performed with a SuperScript II First-Strand Synthesis Kit
(Invitrogen). PCR and qRT-PCR were performed with SYBR-Green Supermix
(Bio-Rad) with the following primers: actin (forward): 50-ctggaacggtgaaggtg
aca-30; actin (reverse): 50-aagggacttcctgtaacaatgca-30; NRG1 (forward; exon
6): 50-tcagtatccacagaaggagcaa-30; and NRG1 (reverse; exon 7): 50-atctcgag
gggtttgaaagg-30.
Spheroid Culture
Multicellular tumor spheroids were generated by the hanging-drop method
(Kelm et al., 2003). A detailed description can be found in Supplemental Exper-
imental Procedures. Where indicated, MM-121, a monoclonal anti-ErbB3
ectodomain antibody from Merrimack Pharmaceuticals, was added to a final
concentration of 25 mg/ml on days 1 and 4 of spheroid formation.
Xenograft Studies
All xenograft studies were conducted under the guidelines of the DFCI Animal
Research Facility with approved protocols. Inducible shErbB3 OVCAR8 cell
lines were transduced with a luciferase-encoding allele as described (Rubin
et al., 2003). OVCAR8 cells carrying different inducible shErbB3 hairpins
were infected with pMMP-LucNeo-producing retrovirus (Rubin et al., 2003),
and stable shRNA/luciferase-producing clones were selected in media con-
taining 0.5 mg/ml G418 (Invitrogen). Xenografts were generated by injecting
1 3 106 cells intraperitoneally into 5- to 6-week-old NCr/nude mice (Taconic).
Mice were anesthetized with a mixture of ketamine hydrochloride (150 mg/kg),
xylazine (12 mg/kg), and D-luciferin (50 mg/ml) (Promega) and imaged using an
In Vivo Imaging System (IVIS; Caliper Life Sciences) for a duration of 5–120 s
per session. Mice recovered from anesthesia under isothermic conditions after
imaging. To quantify bioluminescence, identical standardized circular regions
of interest (ROI) were identified and positioned to encompass the areas of
expected emission, and the integrated flux of photons through each ROI
(photons/s) was quantitated using the Living Images software package
(Caliper Life Sciences).
In a preinjection treatment tumor formation model, luciferase-producing
OVCAR8 cells carrying a stably transfected tet-inducible ErbB3 hairpin
(sh3982) were treated with 0.3 mg/ml doxycycline (Clontech) for 48 hr prior to
mouse injection. Once injected, the recipient mice were continuously fed
doxycycline-containing (2 mg/ml) or doxycycline-free water where indicated.
Mice were then imaged weekly.
In a postinjection treatment model, luciferase-producing OVCAR8-sh3982
and a second, stably transfected, tet-inducible shErbB3-containing line,
OVCAR8-sh3293, were grown in media lacking doxycycline and subsequently
injected into mice. The animals were then imaged every 3–4 days until lucif-
erase activity had increased during two serial measurements. These animals
were then randomly separated into two groups. One was given water contain-
ing doxycycline, and the other group received doxycycline-free water. Subse-
quent imaging was performed weekly.
For the subcutaneous model, 1 3 107 OVCAR8 cells were mixed with
Matrigel (BD Biosciences) at a 1:1 ratio and injected subcutaneously into irra-
diated nude mice. Once a measurable tumor appeared, MM-121 was injected
intraperitoneally at 600 mg/mouse every 2 days. Control mice were injected
with PBS. Tumor volumes were calculated with the formula 0.5*Twidth
2*Tlength.
siRNA and shRNA Sequences
See Supplemental Experimental Procedures for siRNA and shRNA
sequences.SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at
doi:10.1016/j.ccr.2009.12.047.
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